Elacestrant
Drug
Radius Health, Inc.
Total Payments
$26,142
Transactions
30
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $26,142 | 30 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $26,142 | 30 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED MULTICENTER PHASE 2 STUDY OF ELACESTRANT RAD1901 | Radius Health, Inc. | $25,186 | 0 |
| A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT RAD1901 VERSUS INVESTIGATOR'S CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER | Radius Health, Inc. | $956.00 | 0 |
Top Doctors Receiving Payments for Elacestrant
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago Ridge, IL | $26,142 | 30 |
Ad
Manufacturing Companies
- Radius Health, Inc. $26,142
Product Information
- Type Drug
- Total Payments $26,142
- Total Doctors 0
- Transactions 30
About Elacestrant
Elacestrant is a drug associated with $26,142 in payments to 0 healthcare providers, recorded across 30 transactions in the CMS Open Payments database. The primary manufacturer is Radius Health, Inc..
Payment data is available from 2023 to 2023. In 2023, $26,142 was paid across 30 transactions to 0 doctors.
The most common payment nature for Elacestrant is "Unspecified" ($26,142, 100.0% of total).
Elacestrant is associated with 2 research studies, including "A RANDOMIZED MULTICENTER PHASE 2 STUDY OF ELACESTRANT RAD1901" ($25,186).